[HTML][HTML] Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world …
JS Berger, F Laliberté, A Kharat, D Lejeune… - Journal of Thrombosis …, 2022 - Springer
Prior observational studies suggest rivaroxaban is safe and effective among patients with
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in …
JS Berger, F Laliberté, A Kharat… - … of thrombosis and …, 2022 - pubmed.ncbi.nlm.nih.gov
Prior observational studies suggest rivaroxaban is safe and effective among patients with
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
[HTML][HTML] Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world …
JS Berger, F Laliberté, A Kharat, D Lejeune… - … of Thrombosis and …, 2022 - ncbi.nlm.nih.gov
Prior observational studies suggest rivaroxaban is safe and effective among patients with
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in …
JS Berger, F Laliberté, A Kharat, D Lejeune… - … of Thrombosis and …, 2022 - europepmc.org
Prior observational studies suggest rivaroxaban is safe and effective among patients with
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
[PDF][PDF] Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real‑world …
JS Berger, F Laliberté, A Kharat, D Lejeune, KT Moore… - 2022 - academia.edu
Prior observational studies suggest rivaroxaban is safe and effective among patients with
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in …
JS Berger, F Laliberté, A Kharat… - … of Thrombosis and …, 2022 - search.proquest.com
Prior observational studies suggest rivaroxaban is safe and effective among patients with
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in …
JS Berger, F Laliberté, A Kharat, D Lejeune… - … of Thrombosis and …, 2022 - europepmc.org
Prior observational studies suggest rivaroxaban is safe and effective among patients with
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …